Sugi Predict

Sugi Predict / Compounds / SCHEMBL17137102

SCHEMBL17137102

SCHEMBL17137102

CC(C)(C)OC(=O)N1CC=C[C@H]1CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.35
▸ TSHR P16473 4/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ PREP P48147 1/20 0.33
▸ LMNA P02545 3/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ GAA P10253 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ CTSK P43235 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ ATM Q13315 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17137099 1.00 ALDH1A1 (0.35) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL24909113 1.00 ALDH1A1 (0.35) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL22950784 0.88 ATM (0.32) ALDH1A1MEN1KMT2AL3MBTL1PREP
SCHEMBL22950853 0.85 PREP (0.35) ALDH1A1MEN1KMT2APREPLMNA
SCHEMBL24909669 0.82 ALDH1A1 (0.34) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL15320255 0.82 ABHD6 (0.34) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL15320256 0.82 ABHD6 (0.34) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL31567206 0.81 PREP (0.34) ALDH1A1MEN1KMT2APREPLMNA
SCHEMBL15320368 0.81 ALDH1A1 (0.38) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL15320366 0.81 ALDH1A1 (0.38) ALDH1A1TSHRMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202836-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2025-01-21 — — US disclosed
US-20230339960-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER (US) 2023-10-26 — — US disclosed
US-11702424-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2023-07-18 — — US disclosed
US-20200377511-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2020-12-03 — — US disclosed
CN-106458912-B Bicyclic fused heteroaryl or aryl compounds and their use as IRAK4 mimetics 辉瑞公司 2020-10-27 — — CN disclosed
US-10793579-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2020-10-06 — — US disclosed
EP-3536685-A1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS Pfizer Inc (US) 2019-09-11 — — EP disclosed
US-20190270751-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2019-09-05 — — US disclosed
US-10329302-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2019-06-25 — — US disclosed
US-20180127432-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2018-05-10 — — US disclosed
US-9879022-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2018-01-30 — — US disclosed
EP-3126330-A1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS Pfizer Inc (US) 2017-02-08 — — EP disclosed
US-20160347760-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2016-12-01 — — US disclosed
US-9458168-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2016-10-04 — — US disclosed
WO-2015150995-A1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS PFIZER INC. (US) 2015-10-08 — — WO disclosed
US-20150284405-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2015-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347760-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 ALDH1A1 594/4885TSHR 1014/4885MEN1 1506/4885
US-20150284405-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 ALDH1A1 594/4885TSHR 1014/4885MEN1 1506/4885
US-20190270751-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 ALDH1A1 594/4885TSHR 1014/4885MEN1 1506/4885
US-20200377511-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 ALDH1A1 594/4885TSHR 1014/4885MEN1 1506/4885
US-10793579-B2 Bicyclic-fused heteroaryl or aryl compounds UGT2B7, CYP3A43, CYP3A4 ALDH1A1 594/4885TSHR 1014/4885MEN1 1506/4885
US-20230339960-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds TTR, TYR, ABL1 ALDH1A1 1068/4885TSHR 1107/4885MEN1 2394/4885
US-10329302-B2 Bicyclic-fused heteroaryl or aryl compounds UGT2B7, CYP3A43, CYP3A4 ALDH1A1 594/4885TSHR 1014/4885MEN1 1506/4885
US-12202836-B2 Bicyclic-fused heteroaryl or aryl compounds TTR, TYR, ABL1 ALDH1A1 1068/4885TSHR 1107/4885MEN1 2394/4885
US-20180127432-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 ALDH1A1 594/4885TSHR 1014/4885MEN1 1506/4885
US-11702424-B2 Bicyclic-fused heteroaryl or aryl compounds UGT2B7, CYP3A43, CYP3A4 ALDH1A1 594/4885TSHR 1014/4885MEN1 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.